Saudi Arabia’s average life expectancy has climbed to 79.9 years by the end of 2025, up from 74 years in 2016, according to the Health Sector Transformation Program, putting the Kingdom within touching distance of its Vision 2030 target of 80 years. The latest official update also said clinical trials expanded by 51.4 per cent between 2023 and 2025, underscoring how public-health reform and medical research are being presented as twin pillars of the country’s healthcare overhaul.
The new figure marks a further rise from the 78.8 years reported by the Ministry of Health for 2024, showing a steady upward trajectory rather than a single-year jump. Officials have linked the gains to a broad package of prevention-led policies, including early screening for chronic illnesses, stronger awareness campaigns, better access to treatment, and food-policy changes aimed at cutting harmful ingredients such as hydrogenated oils and excessive salt. Those measures have been framed as part of a larger shift away from a system centred mainly on treatment towards one that gives greater weight to prevention, public health and earlier intervention.
That matters because the life-expectancy target has been embedded in Vision 2030 since its launch, when the Kingdom set out to raise the national average from 74 to 80 years by the end of the decade. Hitting 79.9 by end-2025 suggests Saudi Arabia has covered most of that distance with five years still left in the programme window. It also gives the government a headline-friendly indicator of social progress at a time when it is trying to show that economic diversification is being matched by measurable improvements in daily life, public services and human development.
Behind the numbers lies a much broader restructuring of the health sector. The transformation programme aims to improve access, raise service quality and efficiency, promote prevention, and strengthen emergency readiness. Saudi planning documents have long stressed reducing waiting times, widening geographical coverage, improving referrals, expanding digital tools and separating the roles of regulator, provider and financier more clearly across the system. The strategy has also been tied to stronger use of unified records, virtual care and upgraded hospital and primary-care performance.
Clinical research is emerging as a second strand of that story. The official announcement said clinical trials grew by 51.4 per cent between 2023 and 2025, while broader innovation activity in the sector has also accelerated. A Saudi Food and Drug Authority document published in 2025 said clinical studies had risen by 40 per cent in 2024 alone, with 51 early-phase trials and 1,497 study sites evaluated, suggesting the country is trying to build not only a healthier population but also a more competitive biomedical ecosystem. For policymakers, that serves several goals at once: improving patient access to innovative therapies, attracting investment, and positioning Saudi Arabia as a regional hub for regulated medical research.
Still, the rise in life expectancy should not be read as proof that every structural challenge has been settled. Longer lives can reflect better prevention and treatment, but they can also mask pressures that come with ageing populations, higher demand for long-term care, and the growing burden of chronic disease. Saudi Arabia continues to face familiar Gulf health risks, particularly diabetes, obesity and cardiovascular illness, which are precisely the conditions officials cite when they talk about early screening and lifestyle change. Sustaining gains from 79.9 to 80 and beyond may prove harder than the initial climb, especially if reform momentum weakens or health inequalities persist across regions and income groups.
There is also a question of how much of the headline progress comes from policy execution and how much from demographics, better data capture or improved reporting. Saudi authorities have highlighted the role of awareness drives, nutritional regulation and service upgrades, and those claims are broadly consistent with earlier health ministry and programme updates. Independent reporting last year also recorded the move from 74 years in 2016 to 78.8 in 2024 and then 79.7 in 2025, indicating that the latest 79.9 figure represents an incremental extension of an already established trend rather than a sharp statistical break.
For Saudi Arabia, the political value of the figure is as important as the medical one. Life expectancy is one of the clearest benchmarks available to governments seeking to show that transformation is improving lived outcomes. By pairing that number with a sharp increase in clinical trials, officials are arguing that the Kingdom is not only extending lives but also moving up the value chain in healthcare innovation. Whether that narrative holds will depend on what follows next: the durability of prevention reforms, the depth of private and research-sector participation, and whether a nearly met target can be converted into a lasting shift in national health performance.
The new figure marks a further rise from the 78.8 years reported by the Ministry of Health for 2024, showing a steady upward trajectory rather than a single-year jump. Officials have linked the gains to a broad package of prevention-led policies, including early screening for chronic illnesses, stronger awareness campaigns, better access to treatment, and food-policy changes aimed at cutting harmful ingredients such as hydrogenated oils and excessive salt. Those measures have been framed as part of a larger shift away from a system centred mainly on treatment towards one that gives greater weight to prevention, public health and earlier intervention.
That matters because the life-expectancy target has been embedded in Vision 2030 since its launch, when the Kingdom set out to raise the national average from 74 to 80 years by the end of the decade. Hitting 79.9 by end-2025 suggests Saudi Arabia has covered most of that distance with five years still left in the programme window. It also gives the government a headline-friendly indicator of social progress at a time when it is trying to show that economic diversification is being matched by measurable improvements in daily life, public services and human development.
Behind the numbers lies a much broader restructuring of the health sector. The transformation programme aims to improve access, raise service quality and efficiency, promote prevention, and strengthen emergency readiness. Saudi planning documents have long stressed reducing waiting times, widening geographical coverage, improving referrals, expanding digital tools and separating the roles of regulator, provider and financier more clearly across the system. The strategy has also been tied to stronger use of unified records, virtual care and upgraded hospital and primary-care performance.
Clinical research is emerging as a second strand of that story. The official announcement said clinical trials grew by 51.4 per cent between 2023 and 2025, while broader innovation activity in the sector has also accelerated. A Saudi Food and Drug Authority document published in 2025 said clinical studies had risen by 40 per cent in 2024 alone, with 51 early-phase trials and 1,497 study sites evaluated, suggesting the country is trying to build not only a healthier population but also a more competitive biomedical ecosystem. For policymakers, that serves several goals at once: improving patient access to innovative therapies, attracting investment, and positioning Saudi Arabia as a regional hub for regulated medical research.
Still, the rise in life expectancy should not be read as proof that every structural challenge has been settled. Longer lives can reflect better prevention and treatment, but they can also mask pressures that come with ageing populations, higher demand for long-term care, and the growing burden of chronic disease. Saudi Arabia continues to face familiar Gulf health risks, particularly diabetes, obesity and cardiovascular illness, which are precisely the conditions officials cite when they talk about early screening and lifestyle change. Sustaining gains from 79.9 to 80 and beyond may prove harder than the initial climb, especially if reform momentum weakens or health inequalities persist across regions and income groups.
There is also a question of how much of the headline progress comes from policy execution and how much from demographics, better data capture or improved reporting. Saudi authorities have highlighted the role of awareness drives, nutritional regulation and service upgrades, and those claims are broadly consistent with earlier health ministry and programme updates. Independent reporting last year also recorded the move from 74 years in 2016 to 78.8 in 2024 and then 79.7 in 2025, indicating that the latest 79.9 figure represents an incremental extension of an already established trend rather than a sharp statistical break.
For Saudi Arabia, the political value of the figure is as important as the medical one. Life expectancy is one of the clearest benchmarks available to governments seeking to show that transformation is improving lived outcomes. By pairing that number with a sharp increase in clinical trials, officials are arguing that the Kingdom is not only extending lives but also moving up the value chain in healthcare innovation. Whether that narrative holds will depend on what follows next: the durability of prevention reforms, the depth of private and research-sector participation, and whether a nearly met target can be converted into a lasting shift in national health performance.
Topics
Saudi Arabia